



Pfizer Provides Comment on COVID-19 White House Meeting

Monday, March 02, 2020 - 03:10pm

NEW YORK, March 2, 2020—Pfizer Inc. (NYSE: PFE) announced that today Pfizer's Chief Scientific Officer Mikael Dolsten participated in a meeting with other pharmaceutical companies about various ways to develop vaccines and therapeutics for COVID-19 held at the White House.

Pfizer was pleased to have been part of the important meeting convened by the President, given the company's leading research expertise, manufacturing capability and capacity, and regulatory experience, to help combat the virus.

The company has recently completed a preliminary assessment of certain antiviral compounds that were previously in development and that inhibited the replication of coronaviruses similar to the one causing COVID-19 in cultured cells. Pfizer is engaging with a third party to screen these compounds under an accelerated timeline and currently expects to have the results back by the end of March. Upon completion of such screening, the company could be in a position to move forward with development depending on the results. Toxicology studies would then need to be completed prior to any clinical development, but if successful, Pfizer hopes to be in the clinic by no later than the end of 2020.

"At Pfizer, we believe the best approach to address COVID-19 is to bring together the resources and know-how from across the pharmaceutical industry to rapidly develop and deliver vaccines and therapeutics," said Mikael Dolsten, Chief Scientific Officer at Pfizer. "We are happy to volunteer our expertise and resources to aid the development and delivery of possible solutions."

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at [Facebook.com/Pfizer](https://www.facebook.com/Pfizer).

Disclosure Notice: The information contained in this release is as of March 2, 2020. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about antiviral compounds that were previously in development and that inhibited the replication of coronaviruses similar to the one causing COVID-19, including their potential benefits and timing, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including uncertainties regarding the results of screening and the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable pre-clinical or clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when drug applications for any potential antiviral compounds may be filed or approved in any jurisdictions, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any such products; and competitive developments. A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its

subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. # # #
Contacts Media Relations: Amy Rose +1 (212) 733-7410Amy.Rose@pfizer.com Investor Relations: Ryan Crowe +1 (212) 733-8160Ryan.Crowe@Pfizer.com